Jinhe Biotechnology Co Ltd Asset Resilience Ratio
Jinhe Biotechnology Co Ltd asset resilience ratio. Jinhe Biotechnology Co Ltd (002688) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Jinhe Biotechnology Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jinhe Biotechnology Co Ltd (2016–2024)
Asset resilience ratio of Jinhe Biotechnology Co Ltd from 2016 to 2024. This chart shows how Jinhe Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read Jinhe Biotechnology Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jinhe Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Jinhe Biotechnology Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.37 Million | 0.02% |
| Total Liquid Assets | CN¥1.37 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Jinhe Biotechnology Co Ltd maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jinhe Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jinhe Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Jinhe Biotechnology Co Ltd Asset Resilience Ratio by Year (2016–2024)
Jinhe Biotechnology Co Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Jinhe Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | CN¥553.12K ≈ $80.94K |
CN¥5.65 Billion ≈ $826.86 Million |
+0.00pp |
| 2023-12-31 | 0.01% | CN¥507.66K ≈ $74.29K |
CN¥5.45 Billion ≈ $798.06 Million |
+0.16pp |
| 2021-12-31 | -0.15% | CN¥-6.24 Million ≈ $-912.65K |
CN¥4.06 Billion ≈ $594.77 Million |
+0.26pp |
| 2020-12-31 | -0.41% | CN¥-13.97 Million ≈ $-2.04 Million |
CN¥3.38 Billion ≈ $494.14 Million |
-0.10pp |
| 2019-12-31 | -0.31% | CN¥-10.34 Million ≈ $-1.51 Million |
CN¥3.34 Billion ≈ $489.37 Million |
-0.37pp |
| 2018-12-31 | 0.06% | CN¥2.14 Million ≈ $313.21K |
CN¥3.34 Billion ≈ $488.07 Million |
+0.26pp |
| 2016-12-31 | -0.20% | CN¥-5.23 Million ≈ $-766.04K |
CN¥2.66 Billion ≈ $389.58 Million |
-- |
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.